In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ionis Pharmaceuticals Inc.

www.ionispharma.com

Latest From Ionis Pharmaceuticals Inc.

BACE Hopes Finally Fizzle As Biogen/Eisai End Elenbecestat Alzheimer's Studies

Biogen investors cheered the end of the company’s investment in the Phase III studies due to an unfavorable risk-benefit ratio – a widely expected result for the last clinical BACE inhibitor program.

Clinical Trials Neurology

Deal Watch: BMS To Tap Early-Stage Breakthroughs In Partnership With BioMotiv

Bristol-Myers Squibb will partner with the biotech accelerator to fund and launch biotechs, with the pharma getting an option to buy. Novartis signs another agreement with IFM months after buying its IFM Tre affiliate.

Deals Business Strategies

GSK Opts In On Ionis’ Antisense Candidates For Hep B

The pharma is taking over a pair of Ionis candidates intended to address the underlying cause of HBV, possibly offering a curative therapy. It’s just the second HBV licensing agreement in 2019, after heavier deal flow in recent years.

Deals Infectious Diseases

After IPO, BridgeBio Looks To Tuck Eidos Back Into Its Flock

Is Eidos a goose that could lay a golden egg? BridgeBio wants to own it all, instead of two-thirds, in case its subsidiary's lead program in TTR amyloidosis succeeds in Phase III.

Deals M & A
See All

Company Information

  • Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Cancer
  • Cardiovascular
  • Infectious & Viral Diseases
  • Metabolic Disorders
  • Neurology, Nervous System
  • Ophthalmic
  • Renal System
  • Alias(es)
  • Isis Pharmaceuticals Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Ionis Pharmaceuticals Inc.
  • Senior Management
  • Stanley T Crooke, MD, PhD, Chmn. & CEO
    Elizabeth L Hougen, SVP, Fin. & CFO
    C. Frank Bennett, PhD, SVP, Research
    Sanjay Bhanot, MD, PhD, CMO
    Damien McDevitt, PhD, CBO
    Richard S Geary, PhD, SVP, Dev.
  • Contact Info
  • Ionis Pharmaceuticals Inc.
    Phone: (760) 931-9200
    2855 Gazelle Ct.
    Carlsbad, CA 92010
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register